{"id":"esl-part-ii","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Somnolence"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Diplopia"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Hyponatremia"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL20226","moleculeType":"Protein","molecularWeight":"782.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ESL is a prodrug that is rapidly converted to eslicarbazepine, its active metabolite, which selectively inhibits voltage-gated sodium channels in their inactive state. This stabilization of the inactive channel conformation reduces repetitive neuronal firing and propagation of seizure activity. The drug also has weak inhibitory effects on calcium channels, contributing to its anticonvulsant properties.","oneSentence":"ESL (eslicarbazepine acetate) is a voltage-gated sodium channel blocker that reduces neuronal excitability to prevent seizures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:32.883Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Generalized tonic-clonic seizures (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT00957047","phase":"PHASE3","title":"Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-07","conditions":"Partial Epilepsy","enrollment":395},{"nctId":"NCT00957684","phase":"PHASE3","title":"Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-07","conditions":"Refractory Partial Epilepsy","enrollment":402},{"nctId":"NCT00988156","phase":"PHASE3","title":"Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-12-07","conditions":"Partial Epilepsy in Children and Adolescents","enrollment":304},{"nctId":"NCT00957372","phase":"PHASE3","title":"Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-12","conditions":"Partial Epilepsy","enrollment":253},{"nctId":"NCT01825837","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-03","conditions":"Bipolar I Disorder","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eslicarbazepine acetate (ESL), BIA 2-093"],"phase":"phase_3","status":"active","brandName":"ESL - Part II","genericName":"ESL - Part II","companyName":"Bial - Portela C S.A.","companyId":"bial-portela-c-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ESL (eslicarbazepine acetate) is a voltage-gated sodium channel blocker that reduces neuronal excitability to prevent seizures. Used for Partial-onset seizures (adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}